NO20053920D0 - Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler. - Google Patents
Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.Info
- Publication number
- NO20053920D0 NO20053920D0 NO20053920A NO20053920A NO20053920D0 NO 20053920 D0 NO20053920 D0 NO 20053920D0 NO 20053920 A NO20053920 A NO 20053920A NO 20053920 A NO20053920 A NO 20053920A NO 20053920 D0 NO20053920 D0 NO 20053920D0
- Authority
- NO
- Norway
- Prior art keywords
- remyelination
- paralysis
- administration
- agents
- preparation
- Prior art date
Links
- 208000016192 Demyelinating disease Diseases 0.000 title 1
- 206010012305 Demyelination Diseases 0.000 title 1
- 206010033799 Paralysis Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44217103P | 2003-01-24 | 2003-01-24 | |
US50031603P | 2003-09-05 | 2003-09-05 | |
PCT/US2004/002039 WO2004066932A2 (en) | 2003-01-24 | 2004-01-26 | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053920D0 true NO20053920D0 (no) | 2005-08-23 |
NO20053920L NO20053920L (no) | 2005-10-24 |
Family
ID=32829779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053920A NO20053920L (no) | 2003-01-24 | 2005-08-23 | Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler. |
Country Status (16)
Country | Link |
---|---|
US (2) | US7576101B2 (no) |
EP (4) | EP3527228A1 (no) |
JP (4) | JP2007521249A (no) |
KR (2) | KR20050114212A (no) |
AU (5) | AU2004207535A1 (no) |
CA (2) | CA2514117A1 (no) |
CO (1) | CO5670359A2 (no) |
IL (1) | IL169770A (no) |
MX (2) | MXPA05007823A (no) |
NO (1) | NO20053920L (no) |
PE (1) | PE20040942A1 (no) |
RU (1) | RU2412721C2 (no) |
SK (1) | SK50642005A3 (no) |
TW (2) | TW201311238A (no) |
UY (1) | UY28170A1 (no) |
WO (2) | WO2004066932A2 (no) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
AU2003213231A1 (en) * | 2002-02-25 | 2003-09-09 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
US7576101B2 (en) | 2003-01-24 | 2009-08-18 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
US7595318B2 (en) | 2004-01-23 | 2009-09-29 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
MX2007000228A (es) | 2004-07-08 | 2007-03-30 | Elan Pharm Inc | Antagonistas de vla-4 multivalentes que comprenden porsiones de polietilenglicol. |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
CN103169965A (zh) * | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
NZ556105A (en) * | 2004-12-03 | 2009-12-24 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis |
EP1874821B1 (de) | 2005-04-26 | 2013-04-17 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
EP1888639A1 (en) * | 2005-05-12 | 2008-02-20 | Oncotherapy Science, Inc. | Methods for damaging cells using effector function of anti-dsc2 antibody |
NZ563577A (en) | 2005-05-20 | 2011-04-29 | Elan Pharm Inc | Imidazolone phenylalanine derivatives as VLA-4 antagonists |
US20070106035A1 (en) * | 2005-10-26 | 2007-05-10 | Medivas, Llc | Aromatic di-acid-containing poly (ester amide) polymers and methods of use |
CA2667944A1 (en) * | 2005-10-26 | 2007-05-03 | Medivas, Llc | Aromatic di-acid-containing poly (ester amide) polymers and methods of use |
US8017612B2 (en) * | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
US9008378B2 (en) | 2006-12-20 | 2015-04-14 | The Board Of Trustees Of The Leland Stanford Junior University | Arrangement and imaging of biological samples |
US20100221180A1 (en) * | 2007-08-31 | 2010-09-02 | Yanming Wang | In vivo imaging of myelination |
WO2010039545A2 (en) * | 2008-09-23 | 2010-04-08 | Georgetown University | 1,2-benzisothiazolinone and isoindolinone derivatives |
MX2011010971A (es) * | 2009-04-17 | 2012-01-19 | Biogen Idec Inc | Composiciones y metodos para tratar leucemia mielogena aguda. |
EP2467159A1 (en) * | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
AU2011239512B2 (en) | 2010-04-16 | 2016-01-21 | Biogen Ma Inc. | Anti-VLA-4 antibodies |
US20130190299A1 (en) * | 2010-06-30 | 2013-07-25 | Victoria Link Ltd. | Methods and compositions for treatment of multiple sclerosis |
LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
EP2640744A4 (en) * | 2010-11-19 | 2014-05-28 | Eisai R&D Man Co Ltd | NEUTRALIZATION OF ANTIBODIES TO CCL20 |
WO2013025897A1 (en) | 2011-08-16 | 2013-02-21 | Georgetown University | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives |
CN110343171A (zh) | 2012-02-29 | 2019-10-18 | 百深公司 | 周围神经的IgG刺激髓鞘再生 |
TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
EP3750560A3 (en) * | 2012-10-09 | 2021-03-24 | Biogen MA Inc. | Combination therapies and uses for treatment of demyelinating disorders |
WO2015048819A1 (en) * | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
WO2015136469A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
KR20160131073A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg4-5에 대해 특이적인 항-라미닌4 항체 |
CA2938945A1 (en) * | 2014-03-13 | 2015-09-17 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
KR102364840B1 (ko) | 2014-11-05 | 2022-02-18 | 삼성전자주식회사 | 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법 |
AU2014413901B2 (en) * | 2014-12-12 | 2021-04-01 | Commonwealth Scientific And Industrial Research Organisation | Dislodgement and release of HSC from the bone marrow stem cell niche using alpha9 integrin antagonists |
WO2016138538A2 (en) * | 2015-02-27 | 2016-09-01 | The General Hospital Corporation | Therapeutic use of integrin-binding antibodies |
JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファvベータ1インテグリン阻害剤及び使用方法 |
CN106316982B (zh) | 2015-06-30 | 2020-08-14 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻嗪酰胺衍生物及其用途 |
US10947311B2 (en) * | 2015-11-20 | 2021-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | VCAM-1 mediated methods and compositions for treating aging-associated impairments |
CN112119089A (zh) * | 2018-05-23 | 2020-12-22 | 瑞士杰特贝林生物制品有限公司 | Cidp的治疗 |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
CA3148613A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
CA2072249C (en) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
AU687790B2 (en) | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
JP2001508020A (ja) * | 1994-06-02 | 2001-06-19 | シエーリング アクチエンゲゼルシヤフト | 多発性硬化症治療用のpde iv阻害剤 |
US6060501A (en) * | 1994-06-02 | 2000-05-09 | Schering Aktiengesellschaft | Combined treatment of multiple sclerosis |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
AU2964295A (en) | 1994-07-11 | 1996-02-09 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
US6001809A (en) | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
US6284473B1 (en) * | 1995-10-02 | 2001-09-04 | Uab Research Foundation | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
US6306384B1 (en) | 1996-10-01 | 2001-10-23 | E-L Management Corp. | Skin battery cosmetic composition |
IL119989A0 (en) * | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
CA2291778A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
ES2257808T3 (es) * | 1997-05-29 | 2006-08-01 | MERCK & CO., INC. (A NEW JERSEY CORP.) | Acidos biarilalcanoicos como inhibidores de adhesion celular. |
US6362341B1 (en) * | 1997-07-31 | 2002-03-26 | Athena Neurosciences, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
US6583139B1 (en) * | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
AR016133A1 (es) * | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
KR20010022405A (ko) * | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Vla-4에 의해 매개된 백혈구 유착을 억제하는설포닐화된 디펩타이드 화합물 |
WO1999006431A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
US7030114B1 (en) * | 1997-07-31 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6489300B1 (en) * | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6423688B1 (en) * | 1997-07-31 | 2002-07-23 | Athena Neurosciences, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
BR9811573A (pt) * | 1997-07-31 | 2000-09-19 | Elan Pharm Inc | Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4 |
US6291453B1 (en) * | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
DE69834642T2 (de) * | 1997-07-31 | 2007-05-03 | Elan Pharmaceuticals, Inc., South San Francisco | Verbindungen mit einer 4-amino-phenylalaningruppe, die die vla-4 vermittelte adhäsion von leukozyten inhibieren |
US6559127B1 (en) * | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6492421B1 (en) * | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
MXPA01007394A (es) * | 1999-01-25 | 2002-04-09 | Wyeth Corp | Compuestos que inhiben la adhesion de leucocitos mediada mediante alfa4 beta1 integrina y cd49d/cd29 (vla-4). |
US6436904B1 (en) * | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
AU2740900A (en) * | 1999-01-29 | 2000-08-18 | Millennium Pharmaceuticals, Inc. | Method of treating demyelinating inflammatory disease using ccr1 antagonists |
US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
ES2415708T3 (es) | 1999-12-16 | 2013-07-26 | Biogen Idec Ma Inc. | Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4 |
WO2001054690A1 (en) | 2000-01-28 | 2001-08-02 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
ATE536375T1 (de) * | 2000-05-10 | 2011-12-15 | Mayo Foundation | Menschliche igm antikörper, welche die fähigkeit besitzen, den wiederaufbau der myelinstruktur zu induzieren und deren diagnostische und therapeutische anwendung im zentralen nervensystem |
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
US6653313B2 (en) * | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
US6753135B2 (en) * | 2000-09-20 | 2004-06-22 | Surromed, Inc. | Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders |
AU2003213231A1 (en) * | 2002-02-25 | 2003-09-09 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
US7576101B2 (en) | 2003-01-24 | 2009-08-18 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
US9501219B2 (en) | 2012-01-25 | 2016-11-22 | Oracle International Corporation | 2D line data cursor |
-
2004
- 2004-01-26 US US10/763,539 patent/US7576101B2/en active Active
- 2004-01-26 RU RU2005126728/15A patent/RU2412721C2/ru active
- 2004-01-26 KR KR1020057013695A patent/KR20050114212A/ko active Search and Examination
- 2004-01-26 SK SK5064-2005A patent/SK50642005A3/sk not_active Application Discontinuation
- 2004-01-26 MX MXPA05007823A patent/MXPA05007823A/es not_active Application Discontinuation
- 2004-01-26 KR KR1020127024847A patent/KR101260497B1/ko active IP Right Grant
- 2004-01-26 AU AU2004207535A patent/AU2004207535A1/en not_active Abandoned
- 2004-01-26 JP JP2006503001A patent/JP2007521249A/ja active Pending
- 2004-01-26 EP EP19152970.0A patent/EP3527228A1/en not_active Withdrawn
- 2004-01-26 UY UY28170A patent/UY28170A1/es not_active Application Discontinuation
- 2004-01-26 CA CA002514117A patent/CA2514117A1/en not_active Abandoned
- 2004-01-26 WO PCT/US2004/002039 patent/WO2004066932A2/en active Application Filing
- 2004-01-26 EP EP04705270A patent/EP1592387A4/en not_active Withdrawn
- 2004-01-26 EP EP11008463A patent/EP2484381A1/en not_active Withdrawn
- 2004-01-26 WO PCT/US2004/002028 patent/WO2004066931A2/en active Application Filing
- 2004-01-26 MX MXPA05007843A patent/MXPA05007843A/es unknown
- 2004-01-26 CA CA002514125A patent/CA2514125A1/en not_active Abandoned
- 2004-01-26 US US10/763,424 patent/US20050069541A1/en not_active Abandoned
- 2004-01-26 EP EP04705266A patent/EP1592386A4/en not_active Withdrawn
- 2004-01-26 PE PE2004000100A patent/PE20040942A1/es not_active Application Discontinuation
- 2004-01-26 JP JP2006502997A patent/JP2006516624A/ja active Pending
- 2004-01-26 AU AU2004207536A patent/AU2004207536B2/en not_active Expired - Fee Related
- 2004-01-27 TW TW101146999A patent/TW201311238A/zh unknown
- 2004-01-27 TW TW093101747A patent/TWI428141B/zh not_active IP Right Cessation
-
2005
- 2005-07-19 IL IL169770A patent/IL169770A/en active IP Right Grant
- 2005-08-23 NO NO20053920A patent/NO20053920L/no not_active Application Discontinuation
- 2005-08-24 CO CO05084319A patent/CO5670359A2/es not_active Application Discontinuation
-
2010
- 2010-04-14 AU AU2010201472A patent/AU2010201472A1/en not_active Abandoned
- 2010-08-19 AU AU2010212446A patent/AU2010212446B2/en not_active Expired
-
2011
- 2011-03-22 AU AU2011201262A patent/AU2011201262A1/en not_active Abandoned
- 2011-05-30 JP JP2011121017A patent/JP2011225577A/ja active Pending
-
2013
- 2013-10-07 JP JP2013210543A patent/JP2014040458A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053920D0 (no) | Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler. | |
CY2014028I1 (el) | Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης | |
NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
ATE551100T1 (de) | Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen | |
IS8135A (is) | Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm | |
ES2414872T8 (es) | Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente | |
NO324227B1 (no) | Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer | |
NO2014009I2 (no) | Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser | |
EP1737453A4 (en) | METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS | |
GB0404693D0 (en) | Pharmaceutical preparations for the treatment of ocular surface and other disorders | |
NO340679B1 (no) | Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer | |
NO20055136D0 (no) | Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer | |
DE60232251D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von asthma | |
IS7691A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
NO20053855D0 (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
NO20043370L (no) | N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer | |
CY2018006I2 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
NO20053348D0 (no) | Farmasoytisk sammensetning for behandling av virusangrep. | |
EP1765330A4 (en) | PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS | |
ATE424823T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit | |
NO20031648D0 (no) | Farmasöytiske lösninger av modafinilforbindelser | |
NO326689B1 (no) | Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene | |
ATE406895T1 (de) | 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
IL184849A0 (en) | Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BIOGEN IDEC MA INC, US |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BIOGEN MA INC., US |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |